A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice

Dabaghian, Mehran; Latifi, Ali Mohammad; Tebianian, Majid; Dabaghian, Fariba; Ebrahimi, Seyyed Mahmoud

doi:10.1016/j.antiviral.2015.05.002

Cited by 18 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo attenuation was also associated with higher frequencies of Stop mutations in target organs and a higher loss of infectivity. Additionally, translation of RNAs containing Stop codons would result in truncated proteins that may contribute to a better activation of the immune system 44,45 . Moreover, although non-viable genomes do not replicate, their presence could have further impact through defective interference 46,47 or through an adjuvant effect, as observed for defective interfering genomes 48,49 .…”

Section: Discussionmentioning

confidence: 99%

Attenuation of RNA viruses by redirecting their evolution in sequence space

et al. 2017

View full text Add to dashboard Cite

RNA viruses pose serious threats to human health. Their success relies on their capacity to generate genetic variability and, consequently, on their adaptive potential. We describe a strategy to attenuate RNA viruses by altering their evolutionary potential. We rationally altered the genomes of Coxsackie B3 and influenza A viruses to redirect their evolutionary trajectories towards detrimental regions in sequence space. Specifically, viral genomes were engineered to harbour more serine and leucine codons with nonsense mutation targets: codons that could generate Stop mutations after a single nucleotide substitution. Indeed, these viruses generated more Stop mutations both in vitro and in vivo, accompanied by significant losses in viral fitness. In vivo, the viruses were attenuated, generated high levels of neutralizing antibodies and protected against lethal challenge. Our study demonstrates that cornering viruses in 'risky' areas of sequence space may be implemented as a broad-spectrum vaccine strategy against RNA viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Attenuation of RNA viruses by redirecting their evolution in sequence space

et al. 2017

View full text Add to dashboard Cite

show abstract

“…agonists [78][79][80][81][82][83][84] was designed and validated to have overlapping B cell epitope regions through the IEDB server. The adjuvant sequences have been experimentally evidenced to generate neutralizing antibodies, cytokines and natural killer cells.…”

Section: Discussionmentioning

confidence: 99%

“…The triagonist chimeric adjuvant has the propensity to elicit immune responses to allow for its use as a suitable adjuvant against SARS CoV 2. RS09 [78], TR-433 [79] and a Mtb based Hsp70 partial sequence [80,81] were utilized in this endeavor. An appropriate rigid polar linker (DP) was utilized in this regard.…”

Section: Design Of Adjuvantmentioning

confidence: 99%

In silicodesign of Multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein

Mitra

Pandey

Jain³

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractSARS CoV-2 has particularly been efficient in ensuring that many countries are brought to a standstill. With repercussions ranging from rampant mortality, fear, paranoia and economic recession, the virus has brought together countries in order to look at possible therapeutic countermeasures. With prophylactic interventions possibly months away from being particularly effective, a slew of measures and possibilities concerning the design of vaccines are being worked upon. We attempted a structure-based approach utilizing a combination of epitope prediction servers to develop a multi-epitope-based subunit vaccine that involves the two major domains of the spike glycoprotein of SARS CoV-2 (S1 and S2) coupled with a substantially effective chimeric adjuvant to create stable vaccine constructs through MD simulations. The designed constructs were evaluated based on their docking with Toll Like Receptor (TLR) 4. Our findings provide an epitope-based peptide fragment; which can be a potential candidate for the development of a vaccine against SARS-CoV-2. Recent experimental studies based on determining immunodominant regions across the spike glycoprotein of SARS-CoV-2 indicate the presence of the predicted epitopes included in this study.

show abstract

“…The triagonist chimeric adjuvant has the propensity to elicit immune responses to allow for its use as a suitable adjuvant against SARS-CoV-2. RS09 (Shanmugam et al, 2012), TR-433 (Tandon et al, 2018), and an MTB based Hsp70 partial sequence (Dabaghian et al, 2015;Reed et al, 2016) were utilized in this endeavor. An appropriate rigid polar linker (DP) was utilized in this regard.…”

Section: Design Of Adjuvantmentioning

confidence: 99%

In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein

Mitra

Pandey

Jain

et al. 2021

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

SARS-CoV-2 has been efficient in ensuring that many countries are brought to a standstill. With repercussions ranging from rampant mortality, fear, paranoia, and economic recession, the virus has brought together countries to look at possible therapeutic countermeasures. With prophylactic interventions possibly months away from being particularly effective, a slew of measures and possibilities concerning the design of vaccines are being worked upon. We attempted a structure-based approach utilizing a combination of epitope prediction servers and Molecular dynamic (MD) simulations to develop a multi-epitope-based subunit vaccine that involves the two subunits of the spike glycoprotein of SARS-CoV-2 (S1 and S2) coupled with a substantially effective chimeric adjuvant to create stable vaccine constructs. The designed constructs were evaluated based on their docking with Toll-Like Receptor (TLR) 4. Our findings provide an epitope-based peptide fragment that can be a potential candidate for the development of a vaccine against SARS-CoV-2. Recent experimental studies based on determining immunodominant regions across the spike glycoprotein of SARS-CoV-2 indicate the presence of the predicted epitopes included in this study.

show abstract

A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice

Cited by 18 publications

References 41 publications

Attenuation of RNA viruses by redirecting their evolution in sequence space

Attenuation of RNA viruses by redirecting their evolution in sequence space

In silicodesign of Multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein

In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein

Contact Info

Product

Resources

About